HU230759B1 - Teherbeesés megakadályozására és menstruációs tünetek enyhítésére vagy kiküszöbölésére alkalmas orális készítmények - Google Patents
Teherbeesés megakadályozására és menstruációs tünetek enyhítésére vagy kiküszöbölésére alkalmas orális készítmények Download PDFInfo
- Publication number
- HU230759B1 HU230759B1 HU0402651A HUP0402651A HU230759B1 HU 230759 B1 HU230759 B1 HU 230759B1 HU 0402651 A HU0402651 A HU 0402651A HU P0402651 A HUP0402651 A HU P0402651A HU 230759 B1 HU230759 B1 HU 230759B1
- Authority
- HU
- Hungary
- Prior art keywords
- patients
- days
- estrogen
- symptoms
- menstrual
- Prior art date
Links
- 229940127234 oral contraceptive Drugs 0.000 title description 46
- 239000003539 oral contraceptive agent Substances 0.000 title description 46
- 230000035935 pregnancy Effects 0.000 title description 20
- 239000000262 estrogen Substances 0.000 claims description 55
- 229940011871 estrogen Drugs 0.000 claims description 55
- 239000000583 progesterone congener Substances 0.000 claims description 28
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 17
- 229960004400 levonorgestrel Drugs 0.000 claims description 17
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 11
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims description 10
- 229960002568 ethinylestradiol Drugs 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 9
- WAHQVRCNDCHDIB-QZYSPNBYSA-N [(3s,8r,9s,10r,13s,14s,17r)-17-acetyl-17-acetyloxy-6,10,13-trimethyl-1,2,3,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-yl] 3-cyclopentylpropanoate Chemical compound O([C@@H]1C=C2C(C)=C[C@H]3[C@@H]4CC[C@]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)(OC(=O)C)C(C)=O)C(=O)CCC1CCCC1 WAHQVRCNDCHDIB-QZYSPNBYSA-N 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 description 61
- 239000003814 drug Substances 0.000 description 46
- 229940079593 drug Drugs 0.000 description 42
- 238000011282 treatment Methods 0.000 description 38
- 230000002354 daily effect Effects 0.000 description 35
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 28
- 238000002474 experimental method Methods 0.000 description 27
- 230000027758 ovulation cycle Effects 0.000 description 27
- 239000003826 tablet Substances 0.000 description 26
- 230000002175 menstrual effect Effects 0.000 description 20
- 239000003433 contraceptive agent Substances 0.000 description 19
- 238000000034 method Methods 0.000 description 18
- 230000002254 contraceptive effect Effects 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 208000032843 Hemorrhage Diseases 0.000 description 12
- 230000000740 bleeding effect Effects 0.000 description 12
- 229960005309 estradiol Drugs 0.000 description 12
- 229940088597 hormone Drugs 0.000 description 12
- 239000005556 hormone Substances 0.000 description 12
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 11
- 229930182833 estradiol Natural products 0.000 description 11
- 230000002159 abnormal effect Effects 0.000 description 10
- 239000000935 antidepressant agent Substances 0.000 description 10
- 238000012216 screening Methods 0.000 description 9
- 230000002411 adverse Effects 0.000 description 8
- 210000004246 corpus luteum Anatomy 0.000 description 8
- 239000011888 foil Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 7
- 229910052782 aluminium Inorganic materials 0.000 description 7
- 229940000406 drug candidate Drugs 0.000 description 7
- 239000003777 experimental drug Substances 0.000 description 7
- 230000005906 menstruation Effects 0.000 description 7
- 238000009595 pap smear Methods 0.000 description 7
- 238000009597 pregnancy test Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 6
- 230000003821 menstrual periods Effects 0.000 description 6
- 240000003291 Armoracia rusticana Species 0.000 description 5
- 235000011330 Armoracia rusticana Nutrition 0.000 description 5
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 5
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 5
- 206010022998 Irritability Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 229940028334 follicle stimulating hormone Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 230000003054 hormonal effect Effects 0.000 description 5
- 206010025482 malaise Diseases 0.000 description 5
- 239000000186 progesterone Substances 0.000 description 5
- 229960003387 progesterone Drugs 0.000 description 5
- 206010027514 Metrorrhagia Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 206010036618 Premenstrual syndrome Diseases 0.000 description 4
- 206010043268 Tension Diseases 0.000 description 4
- 208000021017 Weight Gain Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 229940124558 contraceptive agent Drugs 0.000 description 4
- 230000002996 emotional effect Effects 0.000 description 4
- 230000001592 luteinising effect Effects 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 208000020016 psychiatric disease Diseases 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- 206010000060 Abdominal distension Diseases 0.000 description 3
- 206010006313 Breast tenderness Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 208000024330 bloating Diseases 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 229960000389 fluoxetine hydrochloride Drugs 0.000 description 3
- 238000009533 lab test Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 239000007935 oral tablet Substances 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 201000000484 premenstrual tension Diseases 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
- 206010055690 Foetal death Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 241001282135 Poromitra oscitans Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 206010046788 Uterine haemorrhage Diseases 0.000 description 2
- 206010048232 Yawning Diseases 0.000 description 2
- 239000006096 absorbing agent Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000009535 clinical urine test Methods 0.000 description 2
- 238000013479 data entry Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 description 2
- 229960003309 dienogest Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 210000001752 female genitalia Anatomy 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 229960002464 fluoxetine Drugs 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940125697 hormonal agent Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 229940096978 oral tablet Drugs 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000001991 scapula Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 229940074158 xanax Drugs 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- XHJMDTAEPZXEKG-SLHNCBLASA-N (8r,9s,13s,14s,17r)-17-ethenyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C=C)[C@@H]4[C@@H]3CCC2=C1 XHJMDTAEPZXEKG-SLHNCBLASA-N 0.000 description 1
- JXQJDYXWHSVOEF-GFEQUFNTSA-N 17alpha-Methylestradiol Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 JXQJDYXWHSVOEF-GFEQUFNTSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000223782 Ciliophora Species 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 101001059930 Drosophila melanogaster Transcription factor kayak, isoforms A/B/F Proteins 0.000 description 1
- 101001059931 Drosophila melanogaster Transcription factor kayak, isoforms D/sro Proteins 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 108010085330 Estradiol Receptors Proteins 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 101000635799 Homo sapiens Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Proteins 0.000 description 1
- 206010020400 Hostility Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001503485 Mammuthus Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000003028 Stuttering Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229940125713 antianxiety drug Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 244000009874 asok Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229960004845 drospirenone Drugs 0.000 description 1
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000000423 heterosexual effect Effects 0.000 description 1
- 239000012051 hydrophobic carrier Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000007644 letterpress printing Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940053544 other antidepressants in atc Drugs 0.000 description 1
- 230000011599 ovarian follicle development Effects 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- -1 oxime hydrochloride Chemical class 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 210000000799 primary oocyte Anatomy 0.000 description 1
- 230000001072 progestational effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 210000004767 rumen Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 208000011293 voice disease Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUS1800033C HUS1800033I1 (hu) | 2001-12-05 | 2018-07-17 | Teherbeesés megakadályozására és menstruációs tünetek enyhítésére vagy kiküszöbölésére alkalmas orális készítmények |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33580701P | 2001-12-05 | 2001-12-05 | |
| US60/335,807 | 2001-12-05 | ||
| PCT/US2002/038602 WO2003049744A1 (en) | 2001-12-05 | 2002-12-04 | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HUP0402651A2 HUP0402651A2 (hu) | 2005-04-28 |
| HUP0402651A3 HUP0402651A3 (en) | 2009-01-28 |
| HU230759B1 true HU230759B1 (hu) | 2018-03-28 |
Family
ID=23313290
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0402651A HU230759B1 (hu) | 2001-12-05 | 2002-12-04 | Teherbeesés megakadályozására és menstruációs tünetek enyhítésére vagy kiküszöbölésére alkalmas orális készítmények |
| HUS1800033C HUS1800033I1 (hu) | 2001-12-05 | 2018-07-17 | Teherbeesés megakadályozására és menstruációs tünetek enyhítésére vagy kiküszöbölésére alkalmas orális készítmények |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUS1800033C HUS1800033I1 (hu) | 2001-12-05 | 2018-07-17 | Teherbeesés megakadályozására és menstruációs tünetek enyhítésére vagy kiküszöbölésére alkalmas orális készítmények |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US7320969B2 (enExample) |
| EP (3) | EP2305229A1 (enExample) |
| JP (3) | JP2005516913A (enExample) |
| CN (2) | CN100581550C (enExample) |
| AU (2) | AU2002348272B2 (enExample) |
| BG (1) | BG108736A (enExample) |
| BR (1) | BRPI0214716B8 (enExample) |
| CA (2) | CA2468748C (enExample) |
| DK (1) | DK1453521T3 (enExample) |
| ES (2) | ES2561491T3 (enExample) |
| FR (1) | FR15C0050I2 (enExample) |
| HU (2) | HU230759B1 (enExample) |
| IL (3) | IL162182A0 (enExample) |
| LU (1) | LU93156I2 (enExample) |
| MX (1) | MXPA04005445A (enExample) |
| NZ (4) | NZ570295A (enExample) |
| PL (1) | PL213122B1 (enExample) |
| PT (1) | PT1453521E (enExample) |
| RU (1) | RU2351339C2 (enExample) |
| SI (1) | SI1453521T1 (enExample) |
| WO (1) | WO2003049744A1 (enExample) |
| ZA (1) | ZA200404249B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5898032A (en) | 1997-06-23 | 1999-04-27 | Medical College Of Hampton Roads | Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy |
| MXPA04005445A (es) | 2001-12-05 | 2005-03-23 | Barr Lab Inc | Anticonceptivos orales para prevenir el embarazo y disminuir la sintomatologia premenstrual. |
| US7005138B2 (en) * | 2001-12-21 | 2006-02-28 | Duramed Pharmaceuticals, Inc. | Method of systematically delivering SSRIs |
| JP2006525358A (ja) * | 2003-05-02 | 2006-11-09 | ドゥラメド ファーマシューティカルズ， インコーポレイテッド | 長期周期避妊養生法を利用するホルモン治療の方法 |
| US20090163454A1 (en) * | 2003-05-02 | 2009-06-25 | Duramed Pharmaceuticals, Inc. | Methods of Step-Down Hormone Treatment |
| US20040222123A1 (en) * | 2003-05-06 | 2004-11-11 | Barr Laboratories, Inc. | Kit for pharmaceuticals |
| NZ585546A (en) * | 2003-07-16 | 2011-10-28 | Teva Womens Health Inc | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
| ATE474795T1 (de) | 2003-09-04 | 2010-08-15 | Pharmadesign Inc | Behälter mit tablettenaufnahmehülsen zur lagerung und ausgabe von tabletten |
| EP1535618A1 (en) * | 2003-11-26 | 2005-06-01 | Schering Aktiengesellschaft | Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions |
| EP1735056B1 (en) | 2004-03-19 | 2012-10-24 | Warner Chilcott Company, LLC | Extended cycle multiphasic oral contraceptive method |
| US20050250746A1 (en) * | 2004-05-06 | 2005-11-10 | Matthew Iammatteo | Premenstrual dysphoric disorder medication |
| EP1755618A1 (en) * | 2004-05-26 | 2007-02-28 | Wyeth a Corporation of the State of Delaware | Compositions and methods for treatment of premenstrual dysphoric disorder |
| WO2006036055A2 (en) * | 2004-09-27 | 2006-04-06 | Pantarhei Bioscience B. V. | Method of female contraception and kit for use in such method |
| MX2007004120A (es) * | 2004-10-07 | 2007-06-15 | Duramed Pharmaceuticals Inc | Metodos de tratamiento hormonal utilizando regimentes de ciclo prolongado de dosis ascendente. |
| US20070111975A1 (en) * | 2004-10-07 | 2007-05-17 | Duramed Pharmaceuticals, Inc. | Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens |
| US20060241092A1 (en) * | 2005-04-15 | 2006-10-26 | Anderson Freedolph D | Contraceptive regimens for lower-weight women |
| TW200726473A (en) * | 2005-06-28 | 2007-07-16 | Wyeth Corp | Compositions and methods for treatment of cycle-related symptoms |
| DE102005056527A1 (de) * | 2005-11-25 | 2007-07-12 | Grünenthal GmbH | Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels |
| DE102006003508A1 (de) * | 2006-01-24 | 2007-07-26 | Grünenthal GmbH | Arzneimittel umfassend eine Hormonkombination |
| ES2558030T3 (es) * | 2006-03-02 | 2016-02-01 | Warner Chilcott Company, Llc | Método anticonceptivo oral multifásico de ciclo prolongado |
| US8399432B2 (en) * | 2009-10-27 | 2013-03-19 | Lipogen Ltd. | Compositions and methods of treatment for alleviating premenstrual syndrome symptoms |
| US9517328B2 (en) | 2013-06-19 | 2016-12-13 | Kashiv Pharma, Llc | Medicament applicator |
| ES2950096T3 (es) | 2016-09-22 | 2023-10-05 | Alan B Cash | Método para aliviar los síntomas del síndrome premenstrual |
| US11679114B2 (en) * | 2021-07-26 | 2023-06-20 | Navad Life Sciences Pte | Progestogen-only oral contraception |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US428051A (en) * | 1890-05-13 | Wood-working machine | ||
| US575690A (en) * | 1897-01-26 | Match-safe | ||
| US3568828A (en) | 1967-03-01 | 1971-03-09 | Squibb & Sons Inc | Modified sequential oral contraceptive |
| US4171358A (en) | 1974-04-19 | 1979-10-16 | Eli Lilly And Company | Novel contraceptive method |
| US4145416A (en) * | 1976-06-23 | 1979-03-20 | Schering, A.G. | Novel agents and novel methods for treatment of climacteric disturbances |
| US4292315A (en) * | 1977-12-30 | 1981-09-29 | Nichols Vorys | Follicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system |
| US4215691A (en) * | 1978-10-11 | 1980-08-05 | Alza Corporation | Vaginal contraceptive system made from block copolymer |
| US4291014A (en) | 1979-01-11 | 1981-09-22 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing estradiol diacetate |
| US4438139A (en) | 1979-08-14 | 1984-03-20 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing estrogens |
| US4390531A (en) | 1981-08-10 | 1983-06-28 | Syntex Pharmaceuticals International Ltd. | Method of contraception using peak progestogen dosage |
| USRE35724E (en) * | 1982-04-28 | 1998-02-03 | Bio-Technology General Corp. | Contraception system and method |
| US4921843A (en) * | 1988-10-20 | 1990-05-01 | Pasquale Samuel A | Contraception system and method |
| US4826831A (en) * | 1983-08-05 | 1989-05-02 | Pre Jay Holdings Limited | Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens |
| US4530839A (en) | 1983-09-26 | 1985-07-23 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
| US4616006A (en) | 1983-09-26 | 1986-10-07 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
| US4628051A (en) | 1983-09-26 | 1986-12-09 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
| US4544554A (en) | 1983-09-26 | 1985-10-01 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
| US4736849A (en) | 1983-12-19 | 1988-04-12 | Leonard Walter G | Calendar-oriented pill dispenser |
| US4534468A (en) | 1983-12-19 | 1985-08-13 | Nuckols Walter S | Calendar-oriented pill dispenser |
| JPS60174716A (ja) | 1984-02-21 | 1985-09-09 | Yamanouchi Pharmaceut Co Ltd | パツチ剤 |
| US4962098A (en) | 1987-06-15 | 1990-10-09 | Warner-Lambert Company | Graduated estrogen contraceptive |
| US5010070A (en) | 1987-06-15 | 1991-04-23 | Warner-Lambert Company | Graduated estrogen contraceptive |
| US4752478A (en) * | 1984-12-17 | 1988-06-21 | Merck & Co., Inc. | Transdermal system for timolol |
| US5208225A (en) * | 1986-02-27 | 1993-05-04 | Warner-Lambert Company | Compositions containing fixed combinations |
| US4762717A (en) | 1986-03-21 | 1988-08-09 | The General Hospital Corporation | Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive |
| IE61236B1 (en) | 1986-07-15 | 1994-10-19 | American Home Prod | Combination dosage form for pre-menopausal women |
| US5256421A (en) * | 1987-09-24 | 1993-10-26 | Jencap Research Ltd. | Hormone preparation and method |
| US5276022A (en) * | 1987-09-24 | 1994-01-04 | Jencap Research Ltd. | Hormone preparation and method |
| US5108995A (en) * | 1987-09-24 | 1992-04-28 | Jencap Research Ltd. | Hormone preparation and method |
| US4971998A (en) * | 1987-10-22 | 1990-11-20 | Massachusetts Institute Of Technology | Methods for treating the premenstrual or late luteal phase syndrome |
| ATE175358T1 (de) * | 1987-10-22 | 1999-01-15 | Massachusetts Inst Technology | Behandlung des prämenstruellen oder späten lutealsphase-syndroms |
| US5043331A (en) * | 1989-06-15 | 1991-08-27 | Orion-Yhtyma Oy | Treatment of postmenopausal disorders |
| US5098714A (en) | 1989-11-16 | 1992-03-24 | Alza Corporation | Osmotic, oral dosage form for fertility control |
| ATE115123T1 (de) * | 1990-10-25 | 1994-12-15 | Schering Corp | Verfahren zur herstellung von florfenicol, seine analoga und oxazolinzwischenprodukte. |
| IE71203B1 (en) | 1990-12-13 | 1997-02-12 | Akzo Nv | Low estrogen oral contraceptives |
| DE4104385C1 (enExample) * | 1991-02-09 | 1992-08-13 | Marika Dr.Med. 6509 Framersheim De Ehrlich | |
| US5211952A (en) * | 1991-04-12 | 1993-05-18 | University Of Southern California | Contraceptive methods and formulations for use therein |
| ZA924811B (en) * | 1991-06-28 | 1993-12-29 | Endorecherche Inc | Controlled release systems and low dose androgens |
| MX9301121A (es) * | 1992-03-02 | 1993-09-01 | Schering Ag | Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina. |
| DE4224534A1 (de) | 1992-07-24 | 1994-01-27 | Marika Dr Med Ehrlich | Ovulationshemmendes Mittel zur hormonalen Kontrazeption |
| NL9301562A (nl) * | 1993-09-09 | 1995-04-03 | Saturnus Ag | Preparaat voor substitutietherapie. |
| DE4344462C2 (de) * | 1993-12-22 | 1996-02-01 | Schering Ag | Zusammensetzung für die Empfängnisverhütung |
| DE4344405C2 (de) * | 1993-12-24 | 1995-12-07 | Marika Dr Med Ehrlich | Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption |
| DE4411585A1 (de) * | 1994-03-30 | 1995-10-05 | Schering Ag | Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption |
| US5552394A (en) * | 1994-07-22 | 1996-09-03 | The Medical College Of Hampton Roads | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
| DE4429374C1 (de) * | 1994-08-12 | 1996-02-01 | Jenapharm Gmbh | Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente |
| DE19513662A1 (de) * | 1995-04-08 | 1996-10-10 | Schering Ag | Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption |
| DE19525017A1 (de) * | 1995-06-28 | 1997-01-02 | Schering Ag | Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption |
| FR2737411B1 (fr) | 1995-08-01 | 1997-10-17 | Theramex | Nouveaux medicaments hormonaux et leur utilisation pour la correction des carences estrogeniques |
| DE19531936A1 (de) | 1995-08-17 | 1997-02-20 | Schering Ag | Kombinationspräparat zur Kontrazeption, Kits diese enthaltend und eine Methode diese verwendend |
| DE19540253C2 (de) | 1995-10-28 | 1998-06-04 | Jenapharm Gmbh | Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene |
| US5747480A (en) * | 1996-05-08 | 1998-05-05 | American Home Products Corporation | Oral contraceptive |
| US6139873A (en) | 1996-07-10 | 2000-10-31 | Cedars-Sinai Medical Center | Combined pharmaceutical estrogen-androgen-progestin |
| WO1998004267A1 (en) * | 1996-07-26 | 1998-02-05 | American Home Products Corporation | Progestin/estrogen oral contraceptive |
| ES2229378T3 (es) * | 1996-07-26 | 2005-04-16 | Wyeth | Anticonceptivo oral. |
| AU3961697A (en) * | 1996-07-26 | 1998-02-20 | American Home Products Corporation | Oral contraceptive |
| US6479475B1 (en) | 1996-07-26 | 2002-11-12 | Wyeth | Oral contraceptive |
| AU3888597A (en) | 1996-07-26 | 1998-02-20 | American Home Products Corporation | Oral contraceptive |
| US5858405A (en) * | 1996-07-26 | 1999-01-12 | American Home Products Corporation | Oral contraceptive |
| AU4043597A (en) * | 1996-07-26 | 1998-02-20 | American Home Products Corporation | Biphasic contraceptive method and kit comprising a combination of a progestin and estrogen |
| US6028064A (en) * | 1996-09-13 | 2000-02-22 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of progestin products |
| US6511970B1 (en) * | 1996-09-13 | 2003-01-28 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium |
| US6765002B2 (en) | 2000-03-21 | 2004-07-20 | Gustavo Rodriguez | Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium |
| DE19705229C2 (de) * | 1997-02-12 | 1999-04-15 | Hesch Rolf Dieter Prof Dr Med | Verwendung von drei Hormonkomponenten zur hormonalen Kontrazeption zur Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen |
| WO1998042671A1 (de) * | 1997-03-20 | 1998-10-01 | Basf Aktiengesellschaft | Substituierte 2-benz(o)ylpyridin derivate, deren herstellung und deren verwendung als herbizide |
| US5898032A (en) | 1997-06-23 | 1999-04-27 | Medical College Of Hampton Roads | Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy |
| US6251956B1 (en) * | 1998-08-20 | 2001-06-26 | Ortho Pharmaceutical Corporation | Combination progestin oral contraceptive regimen |
| DE19739916C2 (de) * | 1997-09-11 | 2001-09-13 | Hesch Rolf Dieter | Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen |
| CN1270521A (zh) | 1997-09-12 | 2000-10-18 | 美国家用产品公司 | 第一阶段包含孕激素/雌激素并且第二阶段包含孕激素的口服避孕制剂 |
| US6306914B1 (en) * | 1997-10-21 | 2001-10-23 | Columbia Laboratories, Inc. | Progestin therapy for maintaining amenorrhea |
| US6265393B1 (en) * | 1998-08-07 | 2001-07-24 | Heinrichs William Leroy | Prevention of endometriosis signs or symptons |
| US6214815B1 (en) | 1998-12-23 | 2001-04-10 | Ortho-Mcneil Pharmaceuticals, Inc. | Triphasic oral contraceptive |
| US6787531B1 (en) * | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
| US20020132801A1 (en) * | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
| US20010044431A1 (en) * | 2000-03-21 | 2001-11-22 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
| MXPA03000170A (es) | 2000-07-06 | 2003-05-27 | Wyeth Corp | Combinaciones de un inhibidor de recaptacion de serotonina selectivo y agentes estrogenicos. |
| CA2446849A1 (en) | 2001-05-16 | 2002-11-21 | Endeavor Pharmaceuticals | Treatment of conditions relating to hormone deficiencies by administration of progestins |
| US20030018018A1 (en) * | 2001-07-10 | 2003-01-23 | Medical College Of Hampton Roads | Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea |
| MXPA04005445A (es) | 2001-12-05 | 2005-03-23 | Barr Lab Inc | Anticonceptivos orales para prevenir el embarazo y disminuir la sintomatologia premenstrual. |
| ES2197801B1 (es) * | 2002-03-05 | 2005-03-16 | Ferrer Internacional,S.A | Procedimiento de obtencion de la 3-(2-(4-(6-fluoro-benzo(d)isoxazol-3-il) piperidin-1-il)-etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido-(1,2-a ) pirimidin-4-ona. |
| US20030229057A1 (en) * | 2002-03-11 | 2003-12-11 | Caubel Patrick Michel | Continuous sulfatase inhibiting progestogen hormone replacement therapy |
| US20030219471A1 (en) | 2002-03-11 | 2003-11-27 | Caubel Patrick Michel | Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens |
| US20040142914A1 (en) * | 2002-03-11 | 2004-07-22 | Friedman Andrew Joseph | Extended transdermal contraceptive regimens |
| BR0309032A (pt) * | 2002-04-03 | 2005-02-01 | Barr Lab Inc | Método para tratar sintomas vasomotores, a menopausa, deficiências hormonais em um paciente, e para tratar um paciente que sofre de sintomas vasomotores |
| JP2006525358A (ja) | 2003-05-02 | 2006-11-09 | ドゥラメド ファーマシューティカルズ， インコーポレイテッド | 長期周期避妊養生法を利用するホルモン治療の方法 |
| US20040251301A1 (en) | 2003-05-05 | 2004-12-16 | Niemann Amy C. | Device for calculating anticipated days for menstruation |
| US20040222123A1 (en) | 2003-05-06 | 2004-11-11 | Barr Laboratories, Inc. | Kit for pharmaceuticals |
| NZ585546A (en) * | 2003-07-16 | 2011-10-28 | Teva Womens Health Inc | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
| ATE474795T1 (de) | 2003-09-04 | 2010-08-15 | Pharmadesign Inc | Behälter mit tablettenaufnahmehülsen zur lagerung und ausgabe von tabletten |
| JP2007507534A (ja) | 2003-10-01 | 2007-03-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 持続的三相避妊方法 |
| US20070111975A1 (en) | 2004-10-07 | 2007-05-17 | Duramed Pharmaceuticals, Inc. | Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens |
| MX2007004120A (es) * | 2004-10-07 | 2007-06-15 | Duramed Pharmaceuticals Inc | Metodos de tratamiento hormonal utilizando regimentes de ciclo prolongado de dosis ascendente. |
| CA2640432A1 (en) * | 2006-01-27 | 2007-08-09 | Duramed Pharmaceuticals, Inc. | Regimens for treatment of conditions related to estrogen deficiency |
-
2002
- 2002-12-04 MX MXPA04005445A patent/MXPA04005445A/es active IP Right Grant
- 2002-12-04 EP EP10181459A patent/EP2305229A1/en not_active Withdrawn
- 2002-12-04 NZ NZ570295A patent/NZ570295A/en not_active IP Right Cessation
- 2002-12-04 PL PL370135A patent/PL213122B1/pl unknown
- 2002-12-04 BR BR0214716A patent/BRPI0214716B8/pt not_active IP Right Cessation
- 2002-12-04 DK DK02782404.4T patent/DK1453521T3/da active
- 2002-12-04 EP EP02782404.4A patent/EP1453521B1/en not_active Revoked
- 2002-12-04 NZ NZ555299A patent/NZ555299A/en not_active IP Right Cessation
- 2002-12-04 CA CA2468748A patent/CA2468748C/en not_active Expired - Lifetime
- 2002-12-04 ES ES10181464.8T patent/ES2561491T3/es not_active Expired - Lifetime
- 2002-12-04 CN CN02824100A patent/CN100581550C/zh not_active Expired - Fee Related
- 2002-12-04 CN CN200910253109A patent/CN101757628A/zh active Pending
- 2002-12-04 EP EP10181464.8A patent/EP2305230B1/en not_active Expired - Lifetime
- 2002-12-04 JP JP2003550793A patent/JP2005516913A/ja active Pending
- 2002-12-04 IL IL16218202A patent/IL162182A0/xx unknown
- 2002-12-04 PT PT2782404T patent/PT1453521E/pt unknown
- 2002-12-04 WO PCT/US2002/038602 patent/WO2003049744A1/en not_active Ceased
- 2002-12-04 US US10/309,313 patent/US7320969B2/en not_active Expired - Lifetime
- 2002-12-04 SI SI200231034T patent/SI1453521T1/sl unknown
- 2002-12-04 AU AU2002348272A patent/AU2002348272B2/en not_active Expired
- 2002-12-04 NZ NZ533242A patent/NZ533242A/en not_active IP Right Cessation
- 2002-12-04 HU HU0402651A patent/HU230759B1/hu not_active IP Right Cessation
- 2002-12-04 RU RU2004121155/15A patent/RU2351339C2/ru not_active IP Right Cessation
- 2002-12-04 CA CA2655959A patent/CA2655959C/en not_active Expired - Lifetime
- 2002-12-04 ES ES02782404T patent/ES2428118T3/es not_active Expired - Lifetime
- 2002-12-04 NZ NZ591627A patent/NZ591627A/xx not_active IP Right Cessation
-
2004
- 2004-05-27 IL IL162182A patent/IL162182A/en not_active IP Right Cessation
- 2004-05-27 BG BG108736A patent/BG108736A/bg unknown
- 2004-05-31 ZA ZA2004/04249A patent/ZA200404249B/en unknown
-
2007
- 2007-08-17 US US11/892,014 patent/US7615545B2/en not_active Expired - Fee Related
- 2007-12-06 US US11/951,492 patent/US7858605B2/en not_active Expired - Fee Related
-
2008
- 2008-10-30 AU AU2008237614A patent/AU2008237614B2/en not_active Ceased
-
2010
- 2010-04-07 JP JP2010089063A patent/JP2010180236A/ja not_active Withdrawn
- 2010-05-24 US US12/786,283 patent/US8338396B2/en not_active Expired - Fee Related
- 2010-08-12 IL IL207561A patent/IL207561A0/en not_active IP Right Cessation
-
2012
- 2012-02-24 JP JP2012038404A patent/JP2012107052A/ja active Pending
- 2012-08-30 US US13/600,050 patent/US8680084B2/en not_active Expired - Fee Related
-
2015
- 2015-07-10 FR FR15C0050C patent/FR15C0050I2/fr active Active
-
2016
- 2016-07-20 LU LU93156C patent/LU93156I2/fr unknown
-
2018
- 2018-07-17 HU HUS1800033C patent/HUS1800033I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Klipping et al. | Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen | |
| Bachmann et al. | Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 μg ethinylestradiol and 3 mg drospirenone | |
| AU2004257772B2 (en) | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration | |
| AU2008237614B2 (en) | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology | |
| Suthipongse et al. | An open-label randomized comparative study of oral contraceptives between medications containing 3 mg drospirenone/30 μg ethinylestradiol and 150 μg levonogestrel/30 μg ethinylestradiol in Thai women | |
| Heger-Mahn et al. | Combined ethinylestradiol/gestodene contraceptive patch: two-center, open-label study of ovulation inhibition, acceptability and safety over two cycles in female volunteers | |
| Wiegratz et al. | Effect of extended-cycle regimen with an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on bleeding patterns, safety, acceptance and contraceptive efficacy | |
| Bruni et al. | An open-label, multicentre trial to evaluate the vaginal bleeding pattern of the combined contraceptive vaginal ring NuvaRing® | |
| Palomba et al. | Metformin hydrochloride and recurrent miscarriage in a woman with polycystic ovary syndrome | |
| Rible et al. | Follicular development in a 7-day versus 4-day hormone-free interval with an oral contraceptive containing 20 mcg ethinyl estradiol and 1 mg norethindrone acetate | |
| Reid et al. | Safety and bleeding profile of continuous levonorgestrel 90 mcg/ethinyl estradiol 20 mcg based on 2 years of clinical trial data in Canada | |
| Endrikat et al. | Double-blind, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day versus a 21-day low-dose oral contraceptive regimen containing 20 μg ethinyl estradiol and 75 μg gestodene | |
| Bruni et al. | Hormonal contraception | |
| Poindexter et al. | Efficacy and safety of a 28-day oral contraceptive with 7 days of low-dose estrogen in place of placebo | |
| Regidor et al. | Improvement of dysmenorrhea, menstrual bleeding and continuation rate in women using the new vaginal ring Ornibel® | |
| Gainder et al. | 26 Polycystic Ovarian Syndrome | |
| Anjum et al. | Medical methods of abortion using lowest effective dose of mifepristone and misoprostol: case study of 100 women | |
| Wiebe et al. | Contraceptive failure related to estimated cycle day of conception relative to the start of the last bleeding episode | |
| HK1076716B (en) | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology | |
| MXPA06000467A (en) | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC9A | Change of name, address |
Owner name: TEVA WOMEN'S HEALTH, INC., US Free format text: FORMER OWNER(S): BARR LABORATORIES, INC., US; DURAMED PHARMACEUTICALS, INC., US; DURAMED PHARMACEUTICALS, INC., US; TEVA WOMEN'S HEALTH INC., US |
|
| FH91 | Appointment of a representative |
Free format text: FORMER REPRESENTATIVE(S): DR. VALYON JOZSEFNE, DANUBIA SZABADALMI ES VEDJEGY IRODA KFT., HU Representative=s name: SBGK SZABADALMI UEGYVIVOEI IRODA, HU |
|
| FH92 | Termination of representative |
Representative=s name: DR. VALYON JOZSEFNE, DANUBIA SZABADALMI ES VED, HU |
|
| AA1S | Information on application for a supplementary protection certificate |
Spc suppl protection certif: S1800033 Filing date: 20180717 Expiry date: 20221204 |
|
| GB9A | Succession in title |
Owner name: THERAMEX HQ UK LIMITED, GB Free format text: FORMER OWNER(S): BARR LABORATORIES, INC., US; DURAMED PHARMACEUTICALS, INC., US; DURAMED PHARMACEUTICALS, INC., US; TEVA WOMEN'S HEALTH INC., US; TEVA WOMEN'S HEALTH, INC., US |
|
| HC9A | Change of name, address |
Owner name: THERAMEX HQ UK LIMITED, GB Free format text: FORMER OWNER(S): BARR LABORATORIES, INC., US; DURAMED PHARMACEUTICALS, INC., US; DURAMED PHARMACEUTICALS, INC., US; TEVA WOMEN'S HEALTH INC., US; TEVA WOMEN'S HEALTH, INC., US; THERAMEX HQ UK LIMITED, GB |
|
| MM4A | Lapse of definitive patent protection due to non-payment of fees |